Analysts expect over 2021 rising revenue arGEN-X

Tomorrow the Belgian company arGEN-X will publish its past quarter results. For this year arGEN-X 's revenue will be around 131.68 million euros. This is according to the average of the analysts' estimates. This is hugely more than 2020's revenue of 36.43 million euros.

Historical revenues and results arGEN-X plus estimates 2020

The analysts expect for 2021 a net loss of 652 million euros. Most of the analysts anticipate on a loss per share of 13.65 euros. Based on this the price/earnings-ratio is -15.53.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals an attractive 1.97 percent.

Newest target prices around 253 euros

arGEN-X 's market capitalization is around 9.07 billion euros. The arGEN-X stock was the past 12 months quite unstable. Since last May the stock is even 48 percent higher. This year the stock price moved between 131 and 315 euro.

Historical stock prices arGEN-X

At 14.26 the stock trades 0.14 percent higher at 212 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.